KYTX — Kyverna Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $90.76m
- -$194.30m
- 38
- 52
- 13
- 26
Annual income statement for Kyverna Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 5.66 | 7.03 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 32 | 36.4 | 62.4 | 143 |
| Operating Profit | -26.3 | -29.4 | -62.4 | -143 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -26.4 | -28.9 | -60.4 | -127 |
| Net Income After Taxes | -26.4 | -28.9 | -60.4 | -127 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -26.4 | -28.9 | -60.4 | -127 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -26.4 | -28.9 | -60.4 | -127 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.645 | -0.708 | -1.4 | -3.33 |
| Dividends per Share |